Androgens in serum and the risk of prostate cancer: A nested case- control study from the Janus serum bank in Norway

Cancer Epidemiology Biomarkers and Prevention

Volumn 6, Issue 11, 1997, Pages 967-969

  Vatten, Lars J ^a   Ursin, Giske ^b   Ross, Ronald K ^b   Stanczyk, Frank Z ^c   Lobo, Rogerio A ^d   Harvei, Sverre ^e   Jellum, Egil ^f  

^a University Medical Center   (Norway)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e CANCER REGISTRY OF NORWAY   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANEDIOL;

ADULT; AGED; ARTICLE; BLOOD STORAGE; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; STATISTICAL ANALYSIS;

ADULT; AGED; ANDROGENS; ANDROSTANE-3,17-DIOL; BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; CASE-CONTROL STUDIES; CHOLESTENONE 5 ALPHA-REDUCTASE; DIHYDROTESTOSTERONE; HUMANS; MALE; MIDDLE AGED; NORWAY; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 0030830660     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cheng, E., Lee, C., and Grayhack, J. Endocrinology of the prostate. In: H. Lepor and R. K. Lawson (eds.), Prostate Diseases, pp. 57-71. Philadelphia: W. B. Saunders, 1993.
2. Coffey, D. S. The molecular biology of the prostate. In: H. Lepor and R. K. Lawson (eds.), Prostate Diseases, pp. 28-56. Philadelphia: W. B. Saunders, 1993.
3. Nomura, A. M. Y., and Kolonel, L. N. Prostate cancer: a current perspective. Epidemic!. Rev., 13: 200-227, 1991.
4. Nomura, A. M. Y., Heilbrun, L. K., Stemmermann, G. N., and Judd, H. L. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res., 48: 3515-3517, 1988.
5. Barrett-Connor, E., Garland, C., McPhillips, J. B., Khaw, K. T., and Wingard, D. L. A prospective, population-based study of androstenedione, estrogens, and prostauc cancer. Cancer Res., 50: 169-173, 1990.
6. Hsing, A. W., and Comstock, G. W. Serological precursors of cancer serum hormones and the risk of subsequent prostate cancer. Cancer Epidemiol. Biomark. Prev., 2: 27-32, 1993.
7. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C., and Stampfer, M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst., 88: 1118-1126, 1996.
8. Nomura, A. M. Y., Stemmermann, G. N., Chyou, P. H., Henderson, B. E., and Stanczyk, F. Z. Serum androgens and prostate cancer. Cancer Epidemiol. Biomark. Prev., 5: 621-625, 1996.
9. Guess, H. A., Friedman, G. D., Sadler, M. C., Stanczyk, F. Z., Vogelman, J. H., Imperato-McGinley, J., Lobo, R. A., and Orentreich, N. 5a-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol. Biomark. Prev., 6: 21-24, 1997.
10. Lookingbill, D., Demers, L., Wang, C., Leung, A., Rittmaster, R., and Santen, R. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J. Clin. Endocrinol. Metab., 72: 1242-1248, 1991.
11. Ross, R. K., Bernstein, L., Lobo, R. A., Shimeza, H., Stanczyk, F. Z., Pike, M. C., and Henderson, B. E. 5-α reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339: 887-889, 1992.
12. Horton, R. A. Testicular steroid transport, metabolism, and effects. In: K. L. Becker (ed.). Principles and Practice of Endocrinology and Metabolism, pp. 937-941. Philadelphia: J. B. Lippincott Co., 1990.
13. Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., et al. Tissue distribution and ontogeny of steroid 5α-reductase isoenzyme expression. J. Clin. Invest., 92: 903-910, 1993.
14. Jellum, E., Andersen, A., Lund-Larsen, P. G., Theodorsen, L., and Ørjasæter, H. Experiences of the Janus Serum Bank in Norway. Environ. Health Perspect., 103 (Suppl. 3): 85-88, 1995.
15. Goebelsmann, U., Arce, J. J., Thomeycroft, I. H., and Mishell, D. R., Jr. Serum testosterone concentrations in women throughout the menstrual cycle and following hCG administration. Am. J. Obstet. Gynecol., 119: 445-452, 1974.
16. Serafine, P., Ablan, F., and Lobo, R. A. 5-α-reductase activity in the genital skin of hirsute women. J. Clin. Endocrinol. Metab., 60: 349-355, 1985.
17. Breslow, N., and Day, N. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. IARC Sci. Publ. 32. Lyon, France: IARC, 1980.
18. Stanczyk, F. Z., Skinner, E. C., Mertes, S., Spahn, M. F. et al. Alterations in circulating levels of androgens and PSA during treatment with finasteride in men at high risk for prostate cancer. In: J. J. Li, S. A. Li, J-Å. Gustafsson, S. Nandi, L. I. Sekely, (eds.). Hormonal Carcinogenesis II. Proceedings of the Second International Symposium. New York: Springer-Verlag, 1996.
19. de Lacerda, L., Kowarski, A., Johanson, A. J., Athanasiou, R., and Migeon, C. J. Integrated concentration and circadian variation of plasma testosterone in normal men. J. Clin. Endocrinol. Metab., 57: 366-371, 1973.